Perspective Therapeutics, Inc.
Business
Perspective Therapeutics is a radiopharmaceutical development company pioneering targeted alpha therapies (TATs) using the Lead-212 isotope to deliver radiation to cancer cells. The company develops product candidates for neuroendocrine tumors, melanoma, and solid tumors, paired with imaging diagnostics using Lead-203 for patient selection. Perspective operates a proprietary generator technology and regional manufacturing network to supply clinical trials and future commercialization.
Summary from 10-K filed 2026-03-16
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Grant revenue | 884,000 | 1 | 1 | — | — | |
| Research and development | 84 | 42 | 21 | — | 881,000 | |
| General and administrative | 30 | 27 | 21 | — | 7 | |
| Goodwill impairment | 0 | 24 | 0 | — | — | |
| Loss on disposal of property and equipment | 0 | 27,000 | 0 | — | 305,000 | |
| Total operating expenses | 114 | 92 | 42 | — | 9 | |
| Operating loss | −114 | −91 | −41 | — | −9 | |
| Interest income | 8 | 11 | 934,000 | — | 618,000 | |
| Interest and other expense | −376,000 | −48,000 | — | — | — | |
| Other income from a related party (Note 3) | 1 | 0 | 2,000 | — | 0 | |
| Equity in loss of affiliate | −2,000 | −8,000 | −17,000 | 17,000 | 0 | |
| Total non-operating income, net | 9 | 10 | 835,000 | — | 618,000 | |
| Net loss from continuing operations | −104 | −80 | −40 | — | −8 | |
| Net gain (loss) from discontinued operations | 514,000 | −949,000 | −9 | — | −3 | |
| Net loss before deferred income tax benefit | −104 | −81 | −49 | — | −11 | |
| Deferred income tax benefit | 793,000 | 2 | 3 | — | — | |
| Net loss | −103 | −79 | −47 | — | −11 | |
| Loss from continuing operations, Basic | −1.41 | −1.22 | −1.4 | — | −0.06 | |
| Loss from continuing operations, Diluted | −1.41 | −1.22 | −1.4 | — | — | |
| Gain (loss) from discontinued operations, Basic | 0.01 | −0.01 | −0.34 | — | −0.02 | |
| Gain (loss) from discontinued operations, Diluted | 0.01 | −0.01 | −0.34 | — | — | |
| Basic loss per share | −1.4 | −1.23 | −1.74 | — | −0.08 | |
| Diluted loss per share | −1.4 | −1.23 | −1.74 | — | — | |
| Basic | 74 | 64 | 27 | — | 142 | |
| Diluted | 74 | 64 | 27 | — | — | |
| Unrealized gain (loss) on available-for-sale securities | 161,000 | −51,000 | 0 | — | — | |
| Comprehensive loss | −103 | −79 | −47 | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 31 | 62 | 9 | 21 | 56 | |
| Short-term investments | 114 | 165 | 0 | 23 | — | |
| Accounts receivable, net of allowance for doubtful accounts: $375 and $543 | 6,000 | 116,000 | 1 | 1 | — | |
| Prepaid expenses and other current assets | 4 | 4 | 1 | 443,000 | 435,000 | |
| Total current assets | 148 | 231 | 17 | 53 | 59 | |
| Property and equipment, net | 77 | 57 | 6 | 371,000 | 2 | |
| Right-of-use asset, net | 2 | 2 | 747,000 | 0 | 512,000 | |
| Intangible assets, in-process research and development | 40 | 50 | 50 | 0 | — | |
| Other assets, net | 486,000 | 405,000 | 487,000 | 175,000 | 107,000 | |
| Total assets | 267 | 341 | 98 | 58 | 64 | |
| Accounts payable and accrued expenses | 21 | 10 | 7 | 2 | 966,000 | |
| Lease liability | 623,000 | 957,000 | 46,000 | 0 | 268,000 | |
| Accrued personnel expenses | 7 | 5 | 4 | — | — | |
| Note payable | 56,000 | 52,000 | 49,000 | — | — | |
| Deferred Income (Note 3) | 0 | 1 | 0 | — | — | |
| Total current liabilities | 29 | 18 | 16 | 3 | 2 | |
| Lease liability, net of current portion | 1 | 1 | 780,000 | 0 | 256,000 | |
| Note payable, net of current portion | 2 | 2 | 2 | 0 | — | |
| Deferred Income, net of current portion (Note 3) | 27 | 27 | 0 | — | — | |
| Deferred tax liability | 2 | 2 | 5 | 0 | — | |
| Other noncurrent liabilities | 386,000 | 55,000 | 0 | — | — | |
| Total liabilities | 60 | 50 | 23 | 3 | 3 | |
| Commitments and contingencies (Note 16) | — | — | — | — | — | |
| Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued | 0 | 0 | 0 | 0 | 0 | |
| Common stock: $0.001 par value; authorized 750,000,000 shares; issued 74,337,990 and 70,671,464 shares | 74,000 | 70,000 | 28,000 | 142,000 | 142,000 | |
| Additional paid-in capital | 542 | 522 | 228 | 160 | 160 | |
| Accumulated other comprehensive income (loss) | 110,000 | −51,000 | — | — | — | |
| Accumulated deficit | −335 | −232 | −152 | −106 | −99 | |
| Total stockholders' equity | 207 | 291 | 75 | 55 | 61 | |
| Total liabilities and stockholders' equity | 267 | 341 | 98 | 58 | 64 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-06-30 |
|---|---|---|---|---|---|---|
| Foreign currency adjustments | 250,000 | −65,000 | — | — | — | |
| Depreciation expense and amortization | 3 | 2 | 986,000 | — | — | |
| Loss on disposal of property and equipment | 0 | 27,000 | 22,000 | 305,000 | 0 | |
| Net accretion of discounts on available-for-sale securities | −3 | −607,000 | 0 | — | — | |
| Loss on divestiture | 0 | 59,000 | 4 | 0 | 0 | |
| In-process research and development impairment | 10 | 0 | — | — | — | |
| Share-based compensation | 9 | 5 | 4 | 983,000 | 1 | |
| Other, net | 5,000 | 99,000 | 410,000 | — | — | |
| Accounts receivable | 110,000 | 1 | 198,000 | 284,000 | 405,000 | |
| Inventory related to discontinued operations (Note 4) | 0 | 11,000 | 359,000 | — | — | |
| Interest receivable | −142,000 | −880,000 | 0 | — | — | |
| Prepaid expenses and other current assets | 624,000 | −2 | −325,000 | −151,000 | 46,000 | |
| Accounts payable and accrued expenses | 147,000 | 2 | 2 | 692,000 | 236,000 | |
| Deferred Income | −1 | 28 | 0 | — | — | |
| Accrued personnel expenses | 2 | 4 | 1 | — | — | |
| Other noncurrent liabilities | 331,000 | 55,000 | 0 | — | — | |
| Net cash used in operating activities | −82 | −18 | −37 | −10 | −8 | |
| Additions to property and equipment | −13 | −54 | −1 | −282,000 | −266,000 | |
| Proceeds from the sale of property and equipment | 0 | 335,000 | 0 | — | 0 | |
| Additions to other assets | −135,000 | −72,000 | −18,000 | — | — | |
| Maturities of available-for-sale securities | 174 | 0 | — | — | — | |
| Purchases of available-for-sale securities | −120 | −165 | 0 | — | — | |
| Proceeds from maturity of held-to-maturity investments | 0 | 79 | 23 | — | — | |
| Purchases of held-to-maturity investments | 0 | −79 | 0 | −35 | 0 | |
| Net cash provided by (used in) investing activities | 41 | −219 | 24 | −29 | −284,000 | |
| Repayment of notes payable | −52,000 | −48,000 | −68,000 | 0 | 0 | |
| Proceeds from sales of common stock, pursuant to exercise of warrants, net | 0 | 125,000 | 0 | — | 0 | |
| Proceeds from sales of common stock, pursuant to exercise of options | 371,000 | 1 | 554,000 | 28,000 | 60,000 | |
| Proceeds from the sales of common stock and Pre-funded Warrants, net | 0 | 288 | — | — | — | |
| Proceeds from the issuance of common stock pursuant to the ATM, net | 10 | 0 | — | — | — | |
| Net cash provided by financing activities | 10 | 289 | 785,000 | 28,000 | 56,000 | |
| Net (decrease) increase in cash and cash equivalents | −31 | 52 | −12 | −39 | −8 | |
| Property and equipment in accounts payable and accrued expenses | 10 | 0 | — | — | — | |
| Recognition of operating lease liability and right-of-use asset | 205,000 | 2 | 811,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Perspective Therapeutics, Inc.'s CIK number?
Perspective Therapeutics, Inc.'s SEC CIK number is 0000728387 (728387). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Perspective Therapeutics, Inc.'s SEC filings?
All of Perspective Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Perspective Therapeutics, Inc. last report earnings?
Perspective Therapeutics, Inc. (CATX) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-216777). This is Perspective Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Perspective Therapeutics, Inc.'s most recent earnings 8-K?
Perspective Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-216777. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Perspective Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →